LTG-4090

LTG-4090 is an investigational small-molecule ion channel modulator being developed by Latigo Biotherapeutics as a non-opioid analgesic, reported to target voltage-gated sodium channel Nav1.8 to block peripheral pain signal transmission while minimizing central nervous system exposure. Public reports indicate it is part of Latigo’s ion channel pipeline and is slated for entry into Phase 1 clinical trials in humans, following the company’s lead Nav1.8 inhibitor LTG-001, which has shown favorable Phase 1 safety and pharmacokinetics and received FDA Fast Track designation for acute pain.[7][9][5] LTG-4090 is being positioned for the treatment of acute and potentially chronic pain conditions where selective peripheral Nav1.8 inhibition could provide effective pain relief without the risks associated with opioids.[7][9]